Sanofi (NYSE:SNY)‘s stock had its “neutral” rating reissued by stock analysts at JPMorgan Chase & Co. in a research note issued on Tuesday.
A number of other brokerages also recently issued reports on SNY. UBS Group reaffirmed a “neutral” rating on shares of Sanofi in a report on Friday. Guggenheim assumed coverage on Sanofi in a report on Monday, October 8th. They set a “neutral” rating on the stock. ValuEngine raised Sanofi from a “sell” rating to a “hold” rating in a report on Wednesday, October 17th. Argus increased their target price on Sanofi from $48.00 to $50.00 and gave the company a “buy” rating in a report on Thursday, November 8th. Finally, Wolfe Research assumed coverage on Sanofi in a report on Tuesday, October 23rd. They issued a “market perform” rating on the stock. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating and six have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus target price of $49.50.
Shares of NYSE:SNY opened at $44.55 on Tuesday. The firm has a market cap of $113.74 billion, a PE ratio of 14.23, a price-to-earnings-growth ratio of 2.57 and a beta of 0.71. The company has a debt-to-equity ratio of 0.40, a quick ratio of 0.85 and a current ratio of 1.22. Sanofi has a 1 year low of $37.43 and a 1 year high of $45.86.
In other Sanofi news, major shareholder Sanofi sold 104,552 shares of the stock in a transaction dated Thursday, September 6th. The stock was sold at an average price of $406.68, for a total value of $42,519,207.36. The transaction was disclosed in a filing with the SEC, which is accessible through this link. 1.00% of the stock is currently owned by corporate insiders.
A number of hedge funds have recently bought and sold shares of SNY. Teachers Advisors LLC bought a new position in Sanofi in the third quarter valued at about $31,557,000. FMR LLC increased its position in Sanofi by 7.5% in the third quarter. FMR LLC now owns 8,527,983 shares of the company’s stock worth $380,945,000 after buying an additional 595,125 shares in the last quarter. TIAA CREF Investment Management LLC purchased a new stake in Sanofi in the third quarter worth about $26,081,000. Tocqueville Asset Management L.P. increased its position in Sanofi by 555.7% in the third quarter. Tocqueville Asset Management L.P. now owns 608,836 shares of the company’s stock worth $50,014,000 after buying an additional 515,986 shares in the last quarter. Finally, Sofinnova Ventures Inc purchased a new stake in Sanofi in the third quarter worth about $18,438,000. 7.06% of the stock is currently owned by institutional investors.
Sanofi Company Profile
Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis.
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.